JNJ-90301900

Phase 3Small molecule

JJohnson & Johnson Enterprise Innovation Inc.

JNJ-90301900 is one of 51 small molecule programs targeting Squamous Cell Carcinoma of Head and Neck. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Cell Carcinoma of Head and NeckRecruiting

Carcinoma, Non-Small-Cell LungRecruiting

Carcinoma, Squamous CellRecruiting

Squamous Cell Carcinoma of Head and NeckPhase 1

Recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Recruiting

Carcinoma, Squamous CellPhase 3

Recruiting

Competition

Competitive Landscape

53 competitors in Carcinoma, Non-Small-Cell Lung

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

14 2

Rybrevant

Johnson & Johnson

Phase 3

13 3

Lazcluze

Johnson & Johnson

Phase 3

8 4

Imfinzi

AstraZeneca

Phase 3

7 5

Paraplatin

AAvyxa

Phase 3

16 6

Taxol

Teva

Phase 3

4 7

Tagrisso

AstraZeneca

Phase 3

3 8

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

13 9

Alimta

Rozlytrek

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Carcinoma, Squamous Cell

NCT04892173

Q3 2028

Phase 1Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07219212

Q4 2028

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667908

Clinical

Trials by Indication[1]

Carcinoma, Squamous Cell1 trial

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 3·NCT04892173·500 enrolled

Squamous Cell Carcinoma of Head and Neck1 trial

A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 1·NCT07219212·45 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 2·NCT06667908·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for JNJ-90301900. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-90301900 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-90301900. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Enterprise Innovation Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJohnson & Johnson Enterprise Innovation Inc.

JNJ-90301900

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q4 2028

Trials by Indication[1]

Carcinoma, Squamous Cell1 trial

Squamous Cell Carcinoma of Head and Neck1 trial

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News